These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 6738212

  • 1. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J, Vinzia C, Gómez JM, Morató J.
    Med Clin (Barc); 1984 May 19; 82(19):840-2. PubMed ID: 6738212
    [No Abstract] [Full Text] [Related]

  • 2. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M, Nowicka G, Szostak WB, Kłosiewicz-Latoszek L.
    Kardiol Pol; 1982 May 19; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract] [Full Text] [Related]

  • 3. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L, Mingrone G, Negrini A, De Cunto F, Greco AV.
    Clin Ter; 1981 Jan 15; 96(1):31-8. PubMed ID: 7016409
    [No Abstract] [Full Text] [Related]

  • 4. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K, Krempler F, Schellenberg B, Schlierf G.
    Acta Med Austriaca; 1979 Jan 15; 6(3):90-4. PubMed ID: 547652
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W, Luley C, Scheffler W, Lehmann-Leo W, Schilling A, Wegscheider K.
    Med Welt; 1982 Apr 30; 33(17):631-7. PubMed ID: 7098826
    [No Abstract] [Full Text] [Related]

  • 6. Plafibride treatment and serum lipids in hyperlipoproteinemias.
    Rodriguez F, López IM, Jover E.
    J Med; 1987 Apr 30; 18(3-4):153-63. PubMed ID: 3323393
    [Abstract] [Full Text] [Related]

  • 7. Clinical experience with bezafibrate.
    Schubotz R, Schneider J, Hausmann L, Mühlfellner G, Mühlfellner O, Kaffarnik H.
    Artery; 1980 Apr 30; 8(6):553-9. PubMed ID: 7259534
    [Abstract] [Full Text] [Related]

  • 8. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G, Fragiacomo C, Weidmann P, Bachmann C.
    Schweiz Med Wochenschr; 1980 Dec 06; 110(49):1875-7. PubMed ID: 7455660
    [Abstract] [Full Text] [Related]

  • 9. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
    Ferreira Montero IJ, Gutiérrez Martín M, del Río Ligorit A, Casasnovas Lenguas JA, Cornudella Lacasa R.
    Med Clin (Barc); 1982 May 01; 78(9):380-5. PubMed ID: 7047926
    [No Abstract] [Full Text] [Related]

  • 10. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L, Mingrone G, Ghirlanda G, Manna R, Rebuzzi A, Pala MA, Greco AV.
    Minerva Med; 1980 Feb 11; 71(4):273-8. PubMed ID: 7354946
    [Abstract] [Full Text] [Related]

  • 11. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H, Schneider J, Schubotz R, Zöfel P, Hausmann L, Goebel KM.
    Artery; 1980 Feb 11; 8(6):537-46. PubMed ID: 6114725
    [Abstract] [Full Text] [Related]

  • 12. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B, Gasparini Casari M, DiBlasio P, Zirilli E.
    Arzneimittelforschung; 1981 Feb 11; 31(10a):1863-6. PubMed ID: 7032534
    [Abstract] [Full Text] [Related]

  • 13. Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia.
    Ferreira IJ, del Rio A, González-Viejo N, Vicens B.
    Arzneimittelforschung; 1981 Feb 11; 31(10a):1859-62. PubMed ID: 7032533
    [Abstract] [Full Text] [Related]

  • 14. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J, Martorell J.
    Clin Ther; 1980 Feb 11; 3(4):234-41. PubMed ID: 7273061
    [Abstract] [Full Text] [Related]

  • 15. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C, Schwartzkopff W, Schilling A, Calder D, Scheffler W.
    Artery; 1980 Feb 11; 8(2):128-33. PubMed ID: 7458677
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L, Da Col PG, Feruglio FS, Finazzo L, Rimondi S, Descovich G, Manzato E, Zambon S, Crepaldi G, Siepi D.
    Clin Ther; 1990 Feb 11; 12(6):482-8. PubMed ID: 2289217
    [Abstract] [Full Text] [Related]

  • 17. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F, Szczechowska E.
    Z Gesamte Inn Med; 1981 Jul 01; 36(13):454-7. PubMed ID: 7025475
    [Abstract] [Full Text] [Related]

  • 18. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W, Holm E.
    Fortschr Med; 1986 Apr 03; 104(13):280-2. PubMed ID: 3699655
    [No Abstract] [Full Text] [Related]

  • 19. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P, Weisweiler P.
    Artery; 1980 Apr 03; 7(6):464-70. PubMed ID: 7236016
    [Abstract] [Full Text] [Related]

  • 20. Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
    Neuman MP, Kurlat MI, Neuman J.
    Curr Med Res Opin; 1983 Apr 03; 8(5):358-67. PubMed ID: 6839800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.